Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs JNJ 63871860 (Primary)
- Indications Escherichia coli infections; Urinary tract infections
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 08 Sep 2017 Planned End Date changed from 31 Aug 2017 to 31 Aug 2020.
- 13 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.